

MAR. 30. 2004 2:15PM

GW GLOBAL R&D IS

NO. 8128 P. 1

FACSIMILE COVER SHEET

GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, Research Triangle Park, NC 27709

**RECEIVED
CENTRAL FAX CENTER**

MAR 30 2004

OFFICIAL

To: **ATTN: DAVID LUKTON, EXAMINER
ART UNIT 1653**

Company/Division: **USPTO**

Phone: **571/272-0952**

Fax: **703/872-9306**

From: **Joyce Hartnett (for J. Michael Strickland)**

Company/Division: **GlaxoSmithKline**

Phone: **919/483-9024**

Fax: **919/483-7988**

Date: **March 30, 2004**

Pages to follow: **7**

This message is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, or exempt from disclosure under applicable federal or state law. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited.

**TRANSMITTAL FORM, EXT. OF TIME REQUEST AND RESPONSE TO RESTRICTION
REQUIREMENT**

Application Number: **09/868,395**

Filing Date: **09/06/2001**

Title: **COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES**

First Named Inventor: **ARMOUR, Duncan Robert, et. al.**

Art Unit: **1653**


Examiner: **David Lukton**

Docket Number: **PG3612USW**



Approved for use through 07/01/2006. OMB 0551-0031
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <small>(to be used for all correspondence after initial filing)</small>	Application Number	09/868,395
	Filing Date	September 6, 2001
	First Named Inventor	ARMOUR, Duncan Robert, et. al.
	Art Unit	1653
	Examiner Name	David Lukton
Total Number of Pages in This Submission	Attorney Docket Number	PG3612USW

ENCLOSURES <small>(check all that apply)</small>		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavit(s)/Declaration(s) <input checked="" type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ Remark: _____	<input type="checkbox"/> Alter Allowance communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): _____ _____
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or individual name Signature Date	J. Michael Strickland - Registration No. 47,115  March 30, 2004	

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the		
Typed or printed name	Joyce Hartnett	
Signature		Date March, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and file by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and warranting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on this amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE CENTRAL FAX CENTER

MAR 30 2004

In re Application of : Armour et al.
Serial No. : 09/868,395
Filing Date : September 6, 2001
Title : *Compounds Useful in the Treatment of Inflammatory Diseases*

OFFICIAL

Grp. /A.U. : 1653
Examiner : Lukton, David
Confirmation No. : 8883
Docket No. : PG3612USw

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This Response is submitted to respond to the Office Action mailed February 20, 2004.

Remarks begin on page 2 of this response.

Serial No. 09/868,395
Attorney Docket No. PG3612USw

REMARKS

The Office Action states that restriction to one of the following inventions is required under 35 U.S.C. § 121:

1. Claims 29-44 and 46, drawn to compounds.
2. Claim 45, drawn to a combination.
3. Claim 47, drawn to a method of using compounds.
4. Claim 48, drawn to a method of making compounds.
5. Claims 49, 51, and 52 drawn to synthetic intermediates.
6. Claim 50, drawn to synthetic intermediates.
7. Claims 53 and 54, drawn to synthetic intermediates.
8. Claim 55, drawn to synthetic intermediates.

Applicants hereby elect the invention of Group 1, claims 29-44 and 46, without traverse. This election is made without traverse because the Applicants agree with the Examiner that the invention of Group 1 is separately patentable from the inventions of Groups 2-8. Applicants understand, however, that as Applicants have elected the claims of Group 1, the claims of Groups 3 and 4 will be re-joined for further examination upon a finding that the claims of Group 1 are allowable.

The Office Action further states that Applicants are required to elect a single species from the claims of Group 1. In response to this election of species requirement, Applicants hereby elect the following species for prosecution: (2S)-3-{4-([(4-aminocarbonyl)-1-piperidinyl]carbonyl)oxy}phenyl]-2-[(2S)-4-methyl-2-[(2-methylphenoxy)acetyl]amino]pentanoyl]amino]propanoic acid. Claims 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 42, 43, 44, and 46 are readable on the elected species.


Applicants understand that upon the allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141.

The concerns of the Examiner addressed in full, Applicants respectfully request the examination of the present application and the issuance of a Notice of Allowance forthwith.

Serial No. 09/368,395
Attorney Docket No. PG3612USw

Applicants encourage the Examiner to direct any questions regarding this application to the undersigned, who may be contacted at (919) 483-9024.

Respectfully submitted:



J. Michael Strickland
Attorney for Applicants
Reg. No. 47,115

Date: March 30, 2004
GlaxoSmithKline Inc.
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Tel. (919) 483-9024
Fax: (919) 483-7988